17:54 IST
NSE
Results Correction
Beta Drugs Results Correction
Beta Drugs submitted revised Limited Review Reports for the quarter ended June 2026, correcting the omission of UDINs as requested by the exchange.
Beta Drugs Ltd
- Share price
- ₹1,991.00
- Market cap
- ₹2,207 Cr
- Revenue (annual)
- ₹384.8 Cr
- Net profit (annual)
- ₹41.48 Cr
- P/E (TTM)
- 48.4×Sector 47.4×
- Promoter holding
- 59.10%-5.53% QoQ
- FII holding
- 1.02%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
All
Fund Raise 5Earnings Call 3Board Meeting Date 3Price Movement Clarification 2Other Announcement 2Financial Results 2Board Meeting Outcome 2Share Pledge 1Results Correction 1Regulatory Approval 1Management Change 1Capital Structure Change 1Business Update 1Annual General Meeting 1Acquisition 1
Time
1 announcement with these filters